tbuckley/cabot-search huggingface dataset:
PNEUMOCOCCIC LOBAR PNEUMONIA: A REPORT OF 245 CASES WITH SPECIAL REFERENCE TO SPECIFIC SERUM THERAPY
Authors: Benjamin Horn
Journal: Annals of Internal Medicine (1939)

Article1 January 1939PNEUMOCOCCIC LOBAR PNEUMONIA: A REPORT OF 245 CASES WITH SPECIAL REFERENCE TO SPECIFIC SERUM THERAPYBENJAMIN HORN, B.S., M.D., F.A.C.P.BENJAMIN HORN, B.S., M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-12-7-922 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is our object in this report to present data accumulated between January 1935 and July 1937, in the treatment of lobar pneumonia, particularly with reference to specific serum therapy.It has been our aim to examine carefully the results in the use of specific serum in suitable cases and to compare these results with those obtained in other cases in which, for some reason, serum was not used. We realize that the number of our cases is small compared to figures from larger institutions, but we wish to make our own modest contribution to indicate what good results can...Bibliography1. COLE R: The treatment of pneumonia, ANN. INT. MED., 1936, x, 1-12. Google Scholar2. CECILPLUMMER RLN: Pneumococcus Type I pneumonia, Jr. Am. Med. Assoc., 1930, xcv, 1547-1553. CrossrefGoogle Scholar3. SUTLIFFFINLAND WDM: Type I pneumococcic infections, New England Jr. Med., 1934, ccx, 237-245. CrossrefGoogle Scholar4. Bulletin: Pneumonia Control, Statistics of the Metropolitan Life Insurance Co., 1937, p. 5. Google Scholar5. CECIL RL: Textbook of Medicine, Ed. 1928, p. 29. Google Scholar6. BENJAMINBLANKENHORNRUEGSEGGERSENIOR JEMFA: A study of the diagnosis and treatment of lobar pneumonia according to types and specific serum therapy, ANN. INT. MED., 1937, xi, 437-447. Google Scholar7. CECILBULLOWACHICKERINGCORWIN RLJMHTEH: Community provision for the serum treatment of pneumococcic pneumonia, Jr. Am. Med. Assoc., 1937, cix, 1323-1328. CrossrefGoogle Scholar8. PAINTONULRICH JFHJ: Lobar pneumonia, ANN. INT. MED., 1937, x, 1345-1364. Google Scholar9. List of Hospitals in United States, Jr. Am. Med. Assoc., 1937, cix, 683-691. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Bridgeport, Connecticut*Received for publication November 9, 1937.From the Laboratory of the Bridgeport Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byImmunitätsvorgänge im Verlaufe der mit Sulfonamiden behandelten croupösen Pneumonie 1 January 1939Volume 12, Issue 7Page: 922-931KeywordsPneumoniaResearch designResearch laboratoriesSerotherapy Issue Published: 1 January 1939 PDF downloadLoading ...
Twelve months, treatment with inhaled salmeterol in asthmatic patients
Authors: J. Lötvall, H. Lunde, A. Ullman, H. Törnqvist, N. Svedmyr
Journal: Allergy (1992)

Salmeterol is a new β 2 ‐receptor agonist with a prolonged duration of action after inhalation, exceeding 12 h in most patients. We have performed a 12‐month open follow‐up study on 11 patients with reversible asthma. All patients were given salmeterol inhalations (50 μg twice daily). Additional asthma treatment included inhaled corticosteroids in all patients, and oral slow‐release theophylline or β 2 ‐receptor agonists in a minority of patients (3 and 1, respectively). Before salmeterol treatment was initiated and after 3, 6, 9 and 12 months of salmeterol treatment, a cumulative dose‐response curve to inhaled salbutamol (100, 300 and 900 μg) was performed, and FEV 1 measured. We also evaluated the effect of each salbutamol dose on finger tremor, systemic blood pressure and heart rate. Blood tests, including white blood count and electrolytes, were taken at each visit. After salmeterol treatment was initiated, morning FEV 1 , measured before the morning asthma medication, was significantly improved (p&lt;0.05). The responsiveness to inhaled salbutamol was not decreased during salmeterol treatment, except in one patient with asthma worsening over the study year. Baseline finger tremor measured before salbutamol dose‐response curves, was significantly lower at the 12‐month visit than before treatment was initiated (p&lt;0.05). Effects of salbutamol on systemic blood pressure, heart rate or finger tremor was not significantly changed during salmeterol treatment. We found a successive and significant decrease in blood eosinophils (p&lt;0.05) during the 12 months of salmeterol treatment, when the patient with asthma worsening was excluded in the analysis. Also platelet count was significantly decreased during the treatment period (p&lt; 0.001), although within the normal range for all patients. In the present study, we found no evidence that long‐term treatment with inhaled salmeterol (50 μg twice daily) produced decreased β 2 ‐receptor sensitivity in airways.
Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study Commentary: Iron deficiency and developmental deficit---the jury is still out
Authors: J Williams, A Wolff, A Daly, A MacDonald, A Aukett, I W Booth, S. Logan
Journal: BMJ (1999)

<h3>Abstract</h3> <b>Objective:</b> To compare the effect of unmodified cows' milk and iron supplemented formula milk on psychomotor development in infants from inner city areas when used as the main milk source. <b>Design:</b> Double blind, randomised intervention trial. <b>Setting:</b> Birmingham health centre. <b>Subjects:</b> 100 infants, mean age 7.8 months (range 5.7 to 8.6 months), whose mothers had already elected to use unmodified cows' milk as their infant9s milk source. <b>Intervention:</b> Changing to an iron supplemented formula milk from enrolment to 18 months of age, or continuing with unmodified cows' milk. <b>Main outcome measures:</b> Developmental assessments using Griffiths scales at enrolment and at 18 and 24 months. <b>Results:</b> 85 participants completed the trial. There were no significant differences in haemoglobin concentration between the two groups at enrolment, but by 18 months of age 33% of the unmodified cows' milk group, but only 2% of the iron supplemented group, were anaemic (P&lt;0.001). The experimental groups had Griffiths general quotient scores that were not significantly different at enrolment, but the scores in both groups declined during the study. By 24 months the decrease in the mean scores in the unmodified cows' milk group was 14.7 whereas the decrease in the mean scores in the iron supplemented group was 9.3 (P&lt;0.02, 95% confidence interval 0.4 to 10.4). Mean subquotient scores were considerably lower in the unmodified cows' milk group at 24 months; significantly so for personal and social scores (P&lt;0.02, –5.4 to 17.2). <b>Conclusion:</b> Replacing unmodified cows' milk with an iron supplemented formula milk up to 18 months of age in infants from inner city areas prevents iron deficiency anaemia and reduces the decline in psychomotor development seen in such infants from the second half of the first year.
mda-7/IL-24: Exploiting Cancer's Achilles' Heel
Authors: Irina V. Lebedeva, Moira Sauane, Rahul V. Gopalkrishnan, Devanand Sarkar, Zhao-zhong Su, Pankaj Gupta, John Nemunaitis, Casey Cunningham, Adly Yacoub, Paul Dent, Paul B. Fisher
Journal: Molecular Therapy (2004)

The mda-7/IL-24 cDNA was isolated almost a decade ago in a screen for genes differentially upregulated following growth arrest and terminal differentiation of a human melanoma cell line employed as an in vitro cell differentiation model. The underlying rationale for the screen was that oncogenesis arises from a cellular dedifferentiation process culminating in uncontrolled proliferation and acquisition of invasive and metastatic potential. Identification of genes upregulated during the process of reactivation of faulty or inoperational differentiation maintenance programs was postulated to have cancer gene therapeutic potential. In this context, it is heartening to note that mda-7/IL-24 has made a methodical and progressive journey, from an unidentified novel sequence with little homology to known genes at its time of isolation to currently having the status of a molecule belonging to the IL-10-related family of cytokines, with considerable cancer gene therapeutic potential. Extensive in vitro and in vivo human tumor xenograft studies have established its transformed cell apoptosis-inducing capacity in various model systems. It has recently taken an important step for a candidate cancer gene therapeutic molecule, in the ultimate goal of benchtop to clinic, by being currently utilized in human Phase I/II clinical trials. This review provides a current perspective of our understanding of mda-7/IL-24, including established and more recent information about the molecular properties, specificity of anti-tumor-cell apoptosis-inducing activity, and underlying mechanisms of this action relative to its cancer gene therapeutic potential.
Abstract 8797: Effects of Smoking and Smoking Cessation on Lipids and Lipoproteins: Outcomes from a Randomized Clinical Trial
Authors: Adam D Gepner, Megan E Piper, Heather M Johnson, Michael C Fiore, Timothy B Baker, James H Stein
Journal: Circulation (2010)

Background: Although observational studies and smaller clinical trials, suggest that cigarette smoking is associated with a more atherogenic lipid profile, no studies have prospectively evaluated t...
Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma
Authors: J. A. Fonseca, L. Nogueira‐Silva, M. Morais‐Almeida, L. Azevedo, A. Sa‐Sousa, M. Branco‐Ferreira, L. Fernandes, J. Bousquet
Journal: Allergy (2010)

To cite this article: Fonseca JA, Nogueira‐Silva L, Morais‐Almeida M, Azevedo L, Sa‐Sousa A, Branco‐Ferreira M, Fernandes L, Bousquet J. Validation of a questionnaire (CARAT10) to assess rhinitis and asthma in patients with asthma. Allergy 2010; 65 : 1042–1048. Abstract Background and aim: The Control of Allergic Rhinitis and Asthma Test (CARAT) was developed to be used in the concurrent management of these diseases, as recommended by the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines. However, it was necessary to statistically identify and remove redundant questions and to evaluate the new version’s factor structure, internal consistency and concurrent validity. Methods: In this cross‐sectional study 193 adults with allergic rhinitis and asthma from 15 outpatient clinics in Portugal were included. The CARAT questionnaire was reduced using descriptive analysis, exploratory factor analysis and internal consistency. Spearman’s correlations were used to compare the CARAT scores with a medical evaluation and other measures of control, including the Asthma Control Questionnaire and symptoms’ visual analogue scales. The performance against physician rating of control was summarized using the area under the curve (AUC) from receiver operating characteristic analysis. In addition, CARAT was compared with the physician’s decision to reduce, maintain or increase treatment. Results: The reduced version has 10 questions and 2 factors (CARAT10). The Cronbach’s alpha was 0.85. All correlation coefficients of CARAT10 and factors with the different measures of control met the a priori predictions, ranging from 0.58 to 0.79. The AUC was 0.82. For the physician’s decision groups of reduce, maintain or increase treatment, the mean (IC95%) scores of CARAT10 were 24 (21.4;26.6), 21 (19.4;21.9) and 15 (13.6;16.5), respectively. Conclusion: CARAT10 has high internal consistency and good concurrent validity, making it useful to compare groups in clinical studies.
Abstract 136: Longer Durations of CPR Decrease the Effect of Post--Cardiac Arrest Mild Therapeutic Hypothermia for Good Neurological Outcome
Authors: Christian Wallmüller, Peter Stratil, Fritz Sterz, Harald Herkner, Andreas Schober, Pia Hubner, Stöckl Mathias, Christoph Testori
Journal: Circulation (2014)

Introduction: Ischemia/Reperfusion injury is known as the primary mechanism leading to neurological injury in patients after cardiac arrest. Even a low-flow state, generated by resuscitation efforts, may already initiate deleterious cascades leading to cell death.We hypothesized, that a longer duration of normothermic “low-flow”-state enforces reperfusion damage and therefore is associated with less beneficial effects derived from mild therapeutic hypothermia (MTH) initiated after restoration of spontaneous circulation. Material and Methods: We retrospectively analyzed data collected between 1992 and 2010 from adult patients successfully resuscitated from witnessed out-of-hospital cardiac arrest. The main risk factor was receiving MTH or not. Time from start of resuscitation efforts until restoration of spontaneous circulation (“low-flow”-state) was a priori grouped into quartiles (Quartile 1: 0-11min; Quartile 2: 12-17min; Quartile 3: 18-28min; Quartile 4:>29min). Best neurologic function (CPC 1 or 2) wi...
Abstract 11911: Comparison of Late Catch-Up Phenomenon Between Sirolimus-Eluting Stent and Everolimus-Eluting Stent During 3 Years Follow-Up - a Propensity Matched Study -
Authors: Norihiro Kobayashi, Toshiya Muramatsu, Reiko Tsukahara, Yoshiaki Ito, Hiroshi Ishimori, Keisuke Hirano, Masatsugu Nakano
Journal: Circulation (2014)

Background: Recent studies have suggested the possibility of late catch-up phenomenon after implantation of sirolimus-eluting stent (SES) for coronary artery disease (CAD) compared to bare metal stent. However, little is known about the incidence of late catch-up phenomenon after implantation of everolimus-eluting stent (EES). Methods: Between April 2007 and May 2011, 1234 patients with CAD were treated with SES and 502 patients were treated with EES in our institution. We used a propensity score matching method with 1:1 matching, including 495 patients treated with SES and 495 patients treated with EES. Late catch-up phenomenon which was defined as target lesion restenosis (1 year to 3 years) were compared between the 2 groups. Results: After the propensity matching, no difference was seen in baseline characteristics between the 2 groups. Cumulative incidence of TLR at 3 years was 7.1% in EES group and 13.5% in SES group (P=0.001, log-rank test). Incidence of late catch-up phenomenon was 4.2% in EES group and 7.8% in SES group (P=0.020, log-rank test). Multivariate Cox’s proportional hazard analysis revealed that sirolimus eluting stent usage (HR 4.7, 95%CI 2.8-7.9, P&lt;0.001), hemodialysis (HR 2.7, 95%CI 1.5-4.9, P=0.001), 2 stent use for bifurcation (HR 2.1, 95%CI 1.1-4.1, P=0.028), IVUS usage (HR 0.41, 95%CI 0.27-0.62, P&lt;0.001), and ACS (HR 1.9, 95%CI 1.0-3.4, P=0.038) were independent predictors of late catch up phenomenon. Conclusions: EES was significantly superior to SES in the incidence of late catch-up phenomenon.
Abstract 4190: A survey of the most common methods of group randomization and distribution in preclinical <i>in vivo</i> studies
Authors: Neil O'Brien, Jeffrey L. Kumer, Eric M. Ibsen
Journal: Cancer Research (2014)

Abstract To more closely emulate clinical research methodology and improve clinical relevance, researchers are increasingly utilizing clinically-similar group randomization and distribution methods for oncology studies in animals. One common pre-clinical approach, a random number generator in a spreadsheet, is paradoxically the least clinically-relevant, and subject to manual and transcription errors. This method provides no easy way to exclude animals from distribution based on other qualitative or quantitative data parameters. Due to limitations in spreadsheet software, commercially available pre-clinical trial applications can be used to perform the most recommended randomization and distribution methods based on tumor volume or other parameters: deterministic and matched distribution, pure randomization, stratified sampling randomization and block randomization across multiple numeric parameters. Subjects may be excluded initially based on recorded qualitative observations, and then by acceptable value ranges for numeric parameters. Animals can be randomized iteratively in rolling enrollment studies and previously randomized subjects can be re-randomized into new groups as required on drug-resistance studies. ANOVA results are displayed instantly to ensure similarity between groups. Standardizing randomization and distribution using clinically relevant methods improves the efficiency, clinical relevance, and outcome of animal studies relative to spreadsheet-based methods. Citation Format: Neil O'Brien, Jeffrey L. Kumer, Eric M. Ibsen. A survey of the most common methods of group randomization and distribution in preclinical in vivo studies. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4190. doi:10.1158/1538-7445.AM2014-4190
Abstract 9665: PKA / CREB Pathway Initiates Endothelial and Hematopoietic Cell Differentiation Via Etv2 Induction
Authors: Kohei Yamamizu, Taichi Matsunaga, Shiori Katayama, Jun K. Yamashita
Journal: Circulation (2011)

Kohei Yamamizu, 2011 Finalist and Presenting Author
Victor C. Vaughan
Authors: Howard Markel
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dynamic Nature of Nonculprit Coronary Artery Lesion Morphology in STEMI
Authors: Zhijing Zhao, Bernhard Witzenbichler, Gary S. Mintz, Markus Jaster, So-Yeon Choi, Xiaofan Wu, Yong He, M. Pauliina Margolis, Ovidiu Dressler, Ecaterina Cristea, Helen Parise, Roxana Mehran, Gregg W. Stone, Akiko Maehara
Journal: JACC. Cardiovascular imaging (2013)
Abstract P030: Use of Skilled Nursing Facilities in Heart Failure: Role of Multimorbidity in the Community
Authors: Sheila M McNallan, Alanna M Chamberlain, Jennifer St. Sauver, Susan A Weston, Ruoxiang Jiang, Veronique L Roger
Journal: Circulation (2014)

Background: As the population ages, it has been reported that discharges to skilled nursing facilities (SNF) have increased. Yet, data on SNF utilization in HF are sparse and predictors are not well defined. Objectives: In a community cohort of incident hospitalized HF patients, we evaluated trends in use of SNF from 1987 through 2006 and described predictors of discharge to SNF. Methods: All Olmsted County, MN residents hospitalized with first ever (incident) HF (ICD-9 code 428) from 1987 through 2006 were identified. HF was validated by Framingham criteria. Patients residing in a SNF prior to hospitalization were excluded from the analysis. Using logistic regression, we determined whether referral to SNF had increased over time and identified predictors of referral to SNF. Results: Among 952 patients (mean age 75±13, 47% male), 185 (19%) were referred to a SNF. After adjustment for age and sex, referral of HF patients to SNF did not change from 1987 to 2006 (p=0.849). Patients with a Charlson comorbidity index of 3 or higher were twice as likely to be referred to a SNF (odds ratio: 1.91, 95% CI: 1.36-2.69, adjusted for age and sex). Individual characteristics associated with referral to a SNF are tabulated. After adjustment, the strongest predictor was dementia, followed by older age, anemia, hypertension and diabetes. Conclusion: In the community, approximately one-fifth of hospitalized HF patients are referred to a SNF and this did not change from 1987 to 2006. While older age and cardiovascular-related factors (hypertension, diabetes) were associated with referral to SNF, non-cardiovascular factors (particularly dementia) were strong predictors of referral. These findings underscore the impact of multimorbidity on HF outcomes.
Therapy of Parkinson's Disease
Authors: Rajesh Pahwa, Kelly E. Lyons, William C. Koller
Journal: Annals of Internal Medicine (1990)

Part 1 History of Parkinson's disease: the history of the medical therapy of Parkinson's disease. Part 2 Assessment, symptoms and sign, and basis of therapy: clinical rating scales and videotape analysis quantitative techniques of assessing motor disability therapies to extend duration of levodopa action magnetic resonance imaging and PET investigations of Parkinson's disease. Part 3 Pharmacologic agents: anticholinergic drugs in the treatment of Parkinson's disease amantadine in Parkinson's disease biochemical basis for levodopa therapy levodopa-based therapy levodopa infusion therapy long-acting levodopa preparations intracerebroventricular infusion of dopaminergic drugs dopamine agonists in Parkinson's disease the influence of bromocriptine on levodopa lisuride - a direct dopamine agonist in the treatment of Parkinson's disease pergolide. Part 4 Surgical approaches: stereotactic thalamotomies the effects of unilateral ventral-posterior medical pallidotoing in patients with Parkinson's disease and Parkinson's plus syndromes chronic high frequency thalamic stimulation in Parkinson's disease scientific basis for dopaminergic brain grafting transplantation of adrenal medullary tissue to brain in Parkinson's disease neurotransplantation. Part 5 Diet in therapy: dietary issues in the treatment of Parkinsonism management of late Parkinson's disease with L-Dopa - role of dietary protein redistribution. Part 6 Other therapeutic approaches: nondopaminergic therapy in Parkinson's disease treatment of autonomic nervous system disturbances in Parkinson's disease management of behavioral symptoms in Parkinson's disease treatment of depression in Parkinson's disease management of psychosis in Parkinson's disease electroconvulsive therapy in Parkinson's disease. (Part Contents).
Abstract 16168: The Association of Fetuin-a With Incident Cardiovascular Disease Differs by Glycemic Status: The Multi-Ethnic Study of Atherosclerosis
Authors: David E St-Jules, Sarah A Aroner, Ronit Katz, Michael G Shlipak, Michael H Criqui, Bryan Kestenbaum, David S Siscovick, Ian H de Boer, Nancy S Jenny, Matthew J Budoff, Joachim H Ix, Majken K Jensen
Journal: Circulation (2014)

Background: Fetuin-A is a hepatic secretory protein that both promotes insulin resistance and inhibits arterial calcification. Previous studies have suggested that the association of fetuin-A with ...
Abstract 12092: Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO
Authors: Shaun G Goodman, Robert Clare, Karen S Pieper, Stefan K James, Jose C Nicolau, Robert F Storey, Warren J Cantor, Dominick J Angiolillo, Steen Husted, Christopher P Cannon, Ph Gabriel Steg, Kenneth W Mahaffey, Jan Kilhamn, Robert A Harrington, Lars Wallentin
Journal: Circulation (2010)

Background: Conflicting data exist regarding the potential adverse interaction between clopidogrel and proton pump inhibitors (PPIs). PPIs inhibit the cytochrome P450 2C19 isoenzyme and conversion ...